Acorda Therapeutics (ACOR) Reports Q2 Loss of $7.55

August 8, 2023 4:48 PM EDT

Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($7.55). Revenue for the quarter came in at $29.68 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings